S
Spectrum Pharmaceuticals Inc
F:NTR
Spectrum Pharmaceuticals Inc
F:NTR
Price:
0.925
EUR
Market Closed
Market Cap:
€189.9m
Balance Sheet
Balance Sheet Decomposition
Spectrum Pharmaceuticals Inc
Spectrum Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
Spectrum Pharmaceuticals Inc
Spectrum Pharmaceuticals Inc
Balance Sheet
Spectrum Pharmaceuticals Inc
Spectrum Pharmaceuticals Inc
Currency: USD
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
156
|
130
|
140
|
158
|
227
|
158
|
64
|
46
|
89
|
40
|
|
| Cash Equivalents |
156
|
130
|
140
|
158
|
227
|
158
|
64
|
46
|
89
|
40
|
|
| Short-Term Investments |
4
|
3
|
0
|
0
|
0
|
47
|
160
|
134
|
12
|
35
|
|
| Total Receivables |
57
|
76
|
43
|
46
|
34
|
34
|
10
|
3
|
1
|
14
|
|
| Accounts Receivables |
50
|
71
|
30
|
40
|
32
|
30
|
0
|
0
|
0
|
13
|
|
| Other Receivables |
8
|
5
|
13
|
6
|
2
|
4
|
10
|
2
|
1
|
1
|
|
| Inventory |
14
|
9
|
4
|
9
|
6
|
0
|
0
|
0
|
0
|
9
|
|
| Other Current Assets |
5
|
4
|
4
|
4
|
10
|
13
|
10
|
4
|
2
|
3
|
|
| Total Current Assets |
235
|
223
|
191
|
217
|
278
|
251
|
244
|
187
|
104
|
101
|
|
| PP&E Net |
2
|
1
|
1
|
0
|
1
|
0
|
15
|
6
|
3
|
2
|
|
| PP&E Gross |
2
|
1
|
1
|
0
|
1
|
0
|
15
|
6
|
3
|
0
|
|
| Accumulated Depreciation |
9
|
6
|
7
|
6
|
6
|
7
|
6
|
3
|
3
|
0
|
|
| Intangible Assets |
231
|
230
|
190
|
164
|
137
|
0
|
0
|
0
|
0
|
0
|
|
| Goodwill |
19
|
18
|
18
|
18
|
18
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
2
|
2
|
2
|
1
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
4
|
9
|
5
|
12
|
38
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
9
|
9
|
13
|
17
|
14
|
139
|
4
|
4
|
5
|
0
|
|
| Other Assets |
19
|
18
|
18
|
18
|
18
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
499
N/A
|
490
-2%
|
419
-14%
|
429
+2%
|
487
+14%
|
391
-20%
|
263
-33%
|
197
-25%
|
112
-43%
|
103
-7%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
13
|
9
|
27
|
31
|
34
|
45
|
32
|
34
|
33
|
34
|
|
| Accrued Liabilities |
66
|
79
|
35
|
27
|
27
|
27
|
14
|
14
|
20
|
9
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
38
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
11
|
21
|
15
|
8
|
11
|
27
|
17
|
5
|
0
|
0
|
|
| Total Current Liabilities |
90
|
109
|
76
|
66
|
110
|
98
|
62
|
53
|
53
|
43
|
|
| Long-Term Debt |
92
|
96
|
99
|
97
|
0
|
0
|
0
|
0
|
0
|
29
|
|
| Deferred Income Tax |
7
|
7
|
7
|
7
|
1
|
2
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
29
|
23
|
24
|
24
|
25
|
20
|
11
|
9
|
11
|
4
|
|
| Total Liabilities |
218
N/A
|
236
+8%
|
206
-12%
|
193
-7%
|
136
-29%
|
120
-12%
|
73
-39%
|
63
-14%
|
64
+2%
|
75
+18%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
238
|
283
|
334
|
403
|
502
|
612
|
724
|
885
|
1 044
|
1 119
|
|
| Additional Paid In Capital |
518
|
539
|
552
|
640
|
837
|
887
|
918
|
1 021
|
1 094
|
1 150
|
|
| Other Equity |
1
|
1
|
5
|
2
|
16
|
4
|
4
|
2
|
3
|
3
|
|
| Total Equity |
282
N/A
|
255
-10%
|
213
-16%
|
236
+11%
|
351
+49%
|
271
-23%
|
190
-30%
|
134
-30%
|
48
-65%
|
28
-41%
|
|
| Total Liabilities & Equity |
499
N/A
|
490
-2%
|
419
-14%
|
429
+2%
|
487
+14%
|
391
-20%
|
263
-33%
|
197
-25%
|
112
-43%
|
103
-7%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
64
|
66
|
68
|
81
|
101
|
111
|
113
|
146
|
165
|
203
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
